1. Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results
- Author
-
Brunner, Hermine I., Nanda, Kabita, Toth, Mary, Foeldvari, Ivan, Bohnsack, John, Milojevic, Diana, Rabinovich, C. Egla, Kingsbury, Daniel J., Marzan, Katherine, Chalom, Elizabeth, Horneff, Gerd, Kuester, Rolf-Michael, Dare, Jason A., Trachana, Maria, Jung, Lawrence K., Olson, Judyann, Minden, Kirsten, Quartier, Pierre, Bereswill, Mareike, Kalabic, Jasmina, Kupper, Hartmut, Lovell, Daniel J., Martini, Alberto, Ruperto, Nicolino, Brunner, Hermine I., Nanda, Kabita, Toth, Mary, Foeldvari, Ivan, Bohnsack, John, Milojevic, Diana, Rabinovich, C. Egla, Kingsbury, Daniel J., Marzan, Katherine, Chalom, Elizabeth, Horneff, Gerd, Kuester, Rolf-Michael, Dare, Jason A., Trachana, Maria, Jung, Lawrence K., Olson, Judyann, Minden, Kirsten, Quartier, Pierre, Bereswill, Mareike, Kalabic, Jasmina, Kupper, Hartmut, Lovell, Daniel J., Martini, Alberto, and Ruperto, Nicolino
- Abstract
Objective To evaluate safety and effectiveness of adalimumab (ADA) in polyarticular-course juvenile idiopathic arthritis (JIA) in the STRIVE registry. Methods STRIVE enrolled patients with polyarticular-course JIA into 2 arms based on treatment with methotrexate (MTX) alone or ADA with/without MTX (ADA +/- MTX). Adverse events (AEs) per 100 patient-years of observation time were analyzed by registry arm. Patients who entered the registry within 4 weeks of starting MTX or ADA +/- MTX, defined as new users, were evaluated for change in disease activity assessed by the 27-joint Juvenile Arthritis Disease Activity Score with the C-reactive protein level (JADAS-27(CRP)). Results At the 7-year cutoff date (June 1, 2016), data from 838 patients were available (MTX arm n = 301, ADA +/- MTX arm n = 537). The most common AEs were nausea (10.3%), sinusitis (4.7%), and vomiting (4.3%) in the MTX arm and arthritis (3.9%), upper respiratory tract infection (3.5%), sinusitis, tonsillitis, and injection site pain (3.0% each) in the ADA +/- MTX arm. Rates of serious infection were 1.5 events/100 patient-years in the MTX arm and 2.0 events/100 patient-years in the ADA +/- MTX arm. AE and serious AE rates were similar in patients receiving ADA with versus without MTX. No deaths or malignancies were reported. New users in the ADA +/- MTX arm showed a trend toward lower mean JADAS-27(CRP)compared with new users in the MTX arm in the first year of STRIVE. Conclusion The STRIVE registry 7-year interim results support the idea that ADA +/- MTX is well tolerated by most children. Registry median ADA exposure was 2.47 (interquartile range 1.0-3.6) years, with 42% of patients continuing ADA at the 7-year cutoff date.
- Published
- 2020